Peter Anton

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate
    Peter A Anton
    Center for HIV Prevention Research, UCLA AIDS Institute, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA
    AIDS Res Hum Retroviruses 28:1412-21. 2012
  2. pmc Future prospects and perspectives on microbicides
    Peter A Anton
    David Geffen School of Medicine and Center for HIV Prevention Research, University of California Los Angeles, Los Angeles, CA, USA
    Curr HIV Res 10:113-5. 2012
  3. pmc Effective in vivo and ex vivo gene transfer to intestinal mucosa by VSV-G-pseudotyped lentiviral vectors
    Hiroshi Matsumoto
    Magee Womens Research Institute, Division of Gastroenterology, Hepatology, and Nutrition, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    BMC Gastroenterol 10:44. 2010
  4. pmc Rectal microbicides: clinically relevant approach to the design of rectal specific placebo formulations
    Lin Wang
    Magee Womens Research Institute, Pittsburgh, PA, USA
    AIDS Res Ther 8:12. 2011
  5. pmc First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy
    Peter A Anton
    Center for HIV Prevention Research, UCLA AIDS Institute, Department of Medicine, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California, United States of America
    PLoS ONE 6:e23243. 2011
  6. pmc HIV transmission: time for translational studies to bridge the gap
    Peter Anton
    Center for HIV Prevention Research, Division of Digestive Diseases and UCLA AIDS Institute, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA
    Sci Transl Med 3:77ps11. 2011
  7. pmc Differential immunogenicity of vaccinia and HIV-1 components of a human recombinant vaccine in mucosal and blood compartments
    Peter A Anton
    Center for Prevention Research and the UCLA AIDS Institute, David Geffen School of Medicine at UCLA, USA
    Vaccine 26:4617-23. 2008
  8. ncbi request reprint Increased HIV-1 mucosal replication is associated with generalized mucosal cytokine activation
    Ian McGowan
    Center for HIV and Digestive Diseases, Division of Digestive Diseases, University of California at Los Angeles AIDS Institute, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    J Acquir Immune Defic Syndr 37:1228-36. 2004
  9. ncbi request reprint Impact of health beliefs, quality of life, and the physician-patient relationship on the treatment intentions of inflammatory bowel disease patients
    Amy B Goldring
    Department of Psychology, University of California, Los Angeles 90095 1563, USA
    Health Psychol 21:219-28. 2002
  10. pmc HIV-1 Nef sequence and functional compartmentalization in the gut is not due to differential cytotoxic T lymphocyte selective pressure
    Martha J Lewis
    Department of Medicine, Division of Infectious Diseases, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America UCLA AIDS Institute, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America
    PLoS ONE 8:e75620. 2013

Collaborators

Detail Information

Publications25

  1. pmc RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate
    Peter A Anton
    Center for HIV Prevention Research, UCLA AIDS Institute, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California 90095, USA
    AIDS Res Hum Retroviruses 28:1412-21. 2012
    ..On the basis of increased gastrointestinal AEs, rectally applied, vaginally formulated TFV was not entirely safe or acceptable, suggesting the need for alternative rectal-specific formulations...
  2. pmc Future prospects and perspectives on microbicides
    Peter A Anton
    David Geffen School of Medicine and Center for HIV Prevention Research, University of California Los Angeles, Los Angeles, CA, USA
    Curr HIV Res 10:113-5. 2012
    ..These current and future efforts will provide potential insights earlier that at Phase IIb or III in the development pipeline...
  3. pmc Effective in vivo and ex vivo gene transfer to intestinal mucosa by VSV-G-pseudotyped lentiviral vectors
    Hiroshi Matsumoto
    Magee Womens Research Institute, Division of Gastroenterology, Hepatology, and Nutrition, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
    BMC Gastroenterol 10:44. 2010
    ....
  4. pmc Rectal microbicides: clinically relevant approach to the design of rectal specific placebo formulations
    Lin Wang
    Magee Womens Research Institute, Pittsburgh, PA, USA
    AIDS Res Ther 8:12. 2011
    ..abstract:..
  5. pmc First phase 1 double-blind, placebo-controlled, randomized rectal microbicide trial using UC781 gel with a novel index of ex vivo efficacy
    Peter A Anton
    Center for HIV Prevention Research, UCLA AIDS Institute, Department of Medicine, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California, United States of America
    PLoS ONE 6:e23243. 2011
    ..A first-in-Phase 1 assessment of preliminary pharmacodynamics was included by measuring changes in ex vivo HIV-1 suppression in rectal biopsy tissue after exposure to product in vivo...
  6. pmc HIV transmission: time for translational studies to bridge the gap
    Peter Anton
    Center for HIV Prevention Research, Division of Digestive Diseases and UCLA AIDS Institute, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA
    Sci Transl Med 3:77ps11. 2011
    ..Furthermore, beyond its defined study end points, this well-conducted trial identified new research directions that should be pursued in smaller intensive basic and translational studies...
  7. pmc Differential immunogenicity of vaccinia and HIV-1 components of a human recombinant vaccine in mucosal and blood compartments
    Peter A Anton
    Center for Prevention Research and the UCLA AIDS Institute, David Geffen School of Medicine at UCLA, USA
    Vaccine 26:4617-23. 2008
    ..Although only eight volunteers were studied intensively, the discordance between mucosal and blood responses may highlight mechanisms contributing to recent vaccine failures...
  8. ncbi request reprint Increased HIV-1 mucosal replication is associated with generalized mucosal cytokine activation
    Ian McGowan
    Center for HIV and Digestive Diseases, Division of Digestive Diseases, University of California at Los Angeles AIDS Institute, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA
    J Acquir Immune Defic Syndr 37:1228-36. 2004
    ..The pathologic basis for these observations is unclear but may relate to the success or failure of antiretroviral therapy in controlling mucosal viral replication...
  9. ncbi request reprint Impact of health beliefs, quality of life, and the physician-patient relationship on the treatment intentions of inflammatory bowel disease patients
    Amy B Goldring
    Department of Psychology, University of California, Los Angeles 90095 1563, USA
    Health Psychol 21:219-28. 2002
    ..8% of the variance in medication-taking intention. Findings suggest that an integrative consideration of relationship factors, health beliefs, and health status may help explain treatment intentions among the chronically ill...
  10. pmc HIV-1 Nef sequence and functional compartmentalization in the gut is not due to differential cytotoxic T lymphocyte selective pressure
    Martha J Lewis
    Department of Medicine, Division of Infectious Diseases, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America UCLA AIDS Institute, David Geffen School of Medicine at UCLA, Los Angeles, California, United States of America
    PLoS ONE 8:e75620. 2013
    ..The finding of a functionally distinct population within gut mucosa offers some insight into how HIV-1 may persist in the gut despite fully suppressed plasma viremia on cART. ..
  11. pmc Use of the location-based social networking application GRINDR as a recruitment tool in rectal microbicide development research
    Earl R Burrell
    Department of Epidemiology, School of Public Health, University of California Los Angeles, 650 Charles E Young Drive South, 41 295 Center for Health Sciences, Los Angeles, CA 90095 1772, USA
    AIDS Behav 16:1816-20. 2012
    ..88 vs. 1.10, p < 0.05) than other recruits. Email responses were less successful for enrollment than phone calls (5 vs. 50 %). This approach resulted in successful recruitment of younger and more educated, White identified MSM...
  12. pmc The slippery slope: lubricant use and rectal sexually transmitted infections: a newly identified risk
    Pamina M Gorbach
    Department of Epidemiology, School of Public Health, University of California, Los Angeles, CA 90095 1772, USA
    Sex Transm Dis 39:59-64. 2012
    ..Use of lubricant products is extremely common during receptive anal intercourse (RAI) yet has not been assessed as a risk for acquisition of sexually transmitted infections (STIs)...
  13. ncbi request reprint Modeling the potential impact of rectal microbicides to reduce hiv transmission in bathhouses
    Romulus Breban
    Department of Biomathematics, David Geffen School of Medicine at UCLA, Los Angeles, California, 90024 USA
    Math Biosci Eng 3:459-66. 2006
    ..Our modeling analyses show that even moderately effective rectal microbicides could be very effective prevention tools for reducing transmission in bathhouses and also potentially limit the spread of HIV in the community...
  14. ncbi request reprint Rectal microbicides
    Ian McGowan
    aUniversity of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA bDavid Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA
    Curr Opin HIV AIDS 3:593-8. 2008
    ..In addition, there is increasing awareness of the need to develop rectal specific microbicide formulations...
  15. pmc Binding and transfer of human immunodeficiency virus by DC-SIGN+ cells in human rectal mucosa
    Kevin B Gurney
    Dept of Medicine, Division of Digestive Diseases, David Geffen School of Medicine at UCLA, 2734 MRL, 675 Charles E Young Dr South, Los Angeles, CA 90095 7019, USA
    J Virol 79:5762-73. 2005
    ..DC-SIGN and the IL-10/IL-12 axis may play significant roles in the mucosal transmission and pathogenesis of HIV type 1...
  16. ncbi request reprint Transience of vaccine-induced HIV-1-specific CTL and definition of vaccine "response"
    Beth D Jamieson
    UCLA AIDS Institute and Department of Medicine, Geffen School of Medicine, UCLA Medical Center, University of California, Los Angeles, CA 90095, and Department of Medicine, Massachusetts General Hospital, Boston 02114, USA
    Vaccine 24:3426-31. 2006
    ....
  17. ncbi request reprint A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy
    Steven G Deeks
    University of California, San Francisco, California 94110, USA
    Mol Ther 5:788-97. 2002
    ..Both groups experienced a treatment-related increase in CD4(+) T-cell counts...
  18. ncbi request reprint Multiple measures of HIV burden in blood and tissue are correlated with each other but not with clinical parameters in aviremic subjects
    Peter A Anton
    University of California, Los Angeles, the San Francisco General Hospital, San Francisco, California, USA
    AIDS 17:53-63. 2003
    ..To determine the levels of residual HIV DNA and RNA in blood and gut reservoirs in aviremic patients, assess correlations among compartmental measurements of HIV burden, and evaluate association with clinical parameters...
  19. ncbi request reprint Mucosal immunity and vaccination against HIV
    Thomas Lehner
    Guy s, King s and St Thomas Medical School, Guy s Hospital, London SE1 9RT, England
    AIDS 16:S125-32. 2002
  20. ncbi request reprint Optimization of methods to assess human mucosal T-cell responses to HIV infection
    Barbara L Shacklett
    Gladstone Institute of Virology and Immunology, University of California, San Francisco, CA, USA
    J Immunol Methods 279:17-31. 2003
    ..Taken together, these methods will be useful for studies of mucosal immunity to HIV-1 and other pathogens during natural infection and following vaccination...
  21. ncbi request reprint Challenges for HIV vaccine dissemination and clinical trial recruitment: if we build it, will they come?
    Peter A Newman
    Faculty of Social Work, Centre for Applied Social Research, University of Toronto, Toronto, Ontario, Canada
    AIDS Patient Care STDS 18:691-701. 2004
    ..Social marketing interventions may increase future HIV vaccine uptake and clinical trial participation, and mitigate increases in HIV risk behaviors...
  22. pmc Parallel human immunodeficiency virus type 1-specific CD8+ T-lymphocyte responses in blood and mucosa during chronic infection
    F Javier Ibarrondo
    UCLA AIDS Institute, Department of Medicine, Geffen School of Medicine, UCLA Medical Center, Los Angeles, CA 90095, USA
    J Virol 79:4289-97. 2005
    ..For protective or immunotherapeutic vaccination, it will be important to determine whether immunity is elicited in the mucosa, which is a key site of initial infection and subsequent HIV-1 replication in vivo...
  23. ncbi request reprint An oral supplement enriched with fish oil, soluble fiber, and antioxidants for corticosteroid sparing in ulcerative colitis: a randomized, controlled trial
    Douglas L Seidner
    Department of Gastroenterology A30, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Clin Gastroenterol Hepatol 3:358-69. 2005
    ....
  24. ncbi request reprint Lack of decay of HIV-1 in gut-associated lymphoid tissue reservoirs in maximally suppressed individuals
    Michael A Poles
    Center for Prevention Research at David Geffen School of Medicine, University of California Los Angeles AIDS Institute, University of California Los Angeles, Los Angeles, CA 90095, USA
    J Acquir Immune Defic Syndr 43:65-8. 2006
    ..In well-suppressed patients on highly active antiretroviral therapy, the GALT compartment showed no clear pattern of HIV-1 decay, similar to that in the PBMCs...
  25. ncbi request reprint Characterization of baseline intestinal mucosal indices of injury and inflammation in men for use in rectal microbicide trials (HIV Prevention Trials Network-056)
    Ian McGowan
    Center for Prevention Research in the Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine, University of Clifornia, Los Angeles, Los Angeles, CA, USA
    J Acquir Immune Defic Syndr 46:417-25. 2007
    ..The purpose of this study was to evaluate the biologic stability of mucosal parameters that might be used as endpoints in phase 1 rectal safety studies...

Research Grants8

  1. Role of Immunization Site in Eliciting Mucosal Immunity
    Peter Anton; Fiscal Year: 2001
    ....
  2. Role of Immunization Site in Eliciting Mucosal Immunity
    Peter Anton; Fiscal Year: 2002
    ....
  3. Role of Immunization Site in Eliciting Mucosal Immunity
    Peter Anton; Fiscal Year: 2003
    ....
  4. IMPACT OF CO-RECEPTOR AND HIV VIRAL BURDEN ON GUT MUCOSA
    Peter Anton; Fiscal Year: 2004
    ..b>Peter Anton, to pursue clinical research on the quantification of mucosal viral loads and the characterization of ..
  5. Microbicide Development Program (MDP)
    Peter Anton; Fiscal Year: 2004
    ..The information derived from these studies will be critical for RT development, but will also provide a rational basis for the development of other classes of rectal microbicides. ..
  6. Role of Immunization Site in Eliciting Mucosal Immunity
    Peter Anton; Fiscal Year: 2004
    ....
  7. Compartment-specific topical microbicide formulations
    Peter Anton; Fiscal Year: 2006
    ..These findings will augment the initial IPCP's goals and ensure that the product(s) delivered are more clinically relevant, behaviorally acceptable as well as lay the foundation for future topical microbicide development. ..